Clinical Trials Register

Trials with a EudraCT protocol (23)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

23 result(s) found for: Lymphomas NEC. Displaying page 1 of 2.

EudraCT Number: 2007-003254-28

Sponsor Protocol Number: 782/07

Start Date*: 2008-03-15

Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI

Full Title: RADIOCHEMIOTERAPIA CON TEMOZOLOMIDE CONCOMITANTE E ADIUVANTE NEL TRATTAMENTO DEI LINFOMI CEREBRALI PRIMITIVI DOPO METOTREXATE AD ALTE DOSI: STUDIO DI DOSE ESCALATION

Medical condition: primary central nervous lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10025323	Lymphomas NEC	HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2004-002860-43

Sponsor Protocol Number: SAKK 36/03

Start Date*: 2005-03-31

Sponsor Name:SIAK

Full Title: Master protocol for mantle cell lymphoma A multicenter phase II trial testing Gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma...

Medical condition: patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	6.1		10025323		HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2004-002302-30

Sponsor Protocol Number: 83/2004/U/Sper

Start Date*: 2004-07-20

Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI

Full Title: FMZ Fludarabine, Mitoxantrone, Zevalin regimen a phase II study as front-line treatment in indolent non-follicular non-Hodgkins lymphoma patients

Medical condition: Confirmed histologic diagnosis according to the REAL classification of B-cell indolent lymphoma including small lymphocytic, immunocytoma, and marginal zone lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	6.1		10003900		HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: (No results available)

EudraCT Number: 2013-000686-37

Sponsor Protocol Number: PR-20-5006-C

Start Date*: 2013-09-11

Sponsor Name:Tesaro, Inc.

Full Title: A Phase 1/2a, Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients with Advanced Solid Tumors and Lymphomas

Medical condition: Solid tumors or lymphomas that have failed standard therapies or for which no standard treatment option(s) exist.

Disease:	Version	SOC Term	Classification Code	Term	Level
	19.0	100000004864	10065147	Malignant solid tumor	LLT
	19.0	100000004851	10025324	Lymphomas unspecified NEC	HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed) ES (Completed) PL (Completed)

Trial results: (No results available)

EudraCT Number: 2008-005843-40

Sponsor Protocol Number: PXD101-CLN-19

Start Date*: 2008-11-11

Sponsor Name:Spectrum Pharmaceuticals Inc.

Full Title: A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Medical condition: Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.1	100000004851	10034622	Peripheral T-cell lymphomas NEC	HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Completed) FR (Completed) IT (Completed) NL (Completed) BE (Completed) DE (Completed) ES (Completed) HU (Completed) SK (Completed) PL (Completed) GB (Completed)

Trial results: View results

EudraCT Number: 2007-006246-17

Sponsor Protocol Number: H6Q-MC-S011(b)

Start Date*: 2008-06-12

Sponsor Name:Eli Lilly and Company

Full Title: A Phase 2 Study of Enzastaurin in Patients with Follicular Lymphoma

Medical condition: Grade 1 or 2 follicular lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	17.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10003899	B-cell lymphoma	PT
	17.1	10005329 - Blood and lymphatic system disorders	10025320	Lymphomas non-Hodgkin's B-cell	HLGT
	17.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029473	Nodular (follicular) lymphoma	LLT
	17.1	10005329 - Blood and lymphatic system disorders	10003900	B-cell lymphomas NEC	HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2021-003526-80

Sponsor Protocol Number: CLSG-PTCL-CHEPA

Start Date*: 2021-12-16

Sponsor Name:Kooperativní lymfomová skupina, z.s.

Full Title: A Phase II Open Label Study of Brentuximab Vedotin in combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas.

Medical condition: Peripheral T-cell lymphomas (PTCL)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004851	10002450	Angioimmunoblastic T-cell lymphomas	HLT
	20.0	100000004851	10001414	Adult T-cell lymphomas/leukaemias	HLT
	20.0	100000004851	10022704	Intestinal T-cell lymphomas	HLT
	20.0	100000004851	10034622	Peripheral T-cell lymphomas NEC	HLT
	21.0	100000004864	10002451	Angioimmunoblastic T-cell lymphoma NOS	LLT
	21.0	100000004864	10001415	Adult T-cell lymphoma/leukaemia NOS	LLT
	21.1	100000004864	10076434	Hepatosplenic gamma-delta T-cell lymphoma	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: CZ (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2008-006919-20

Sponsor Protocol Number: AGMT_PTCL1

Start Date*: 2009-09-24

Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH

Full Title: Phase I/II Trial of Lenalidomide in Combination with Vorinostat and Dexamethasone as Therapy in Relapsed or Refractory Patients with Peripheral T-Cell Non-Hodgkin’s Lymphoma (PTCL)

Medical condition: Peripheral T-Cell Non-Hodgkin’s Lymphoma (PTCL)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	13.1	10005329 - Blood and lymphatic system disorders	10034622	Peripheral T-cell lymphomas NEC	HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: AT (Prematurely Ended)

Trial results: View results

EudraCT Number: 2015-005176-17

Sponsor Protocol Number: BP-I-008

Start Date*: 2016-10-20

Sponsor Name:Bellicum Pharmaceuticals, Inc.

Full Title: A Phase I Study of Safety, Pharmacokinetics and Efficacy of Donor BPX-501 Cells and AP1903 Infusion for Children with Recurrent or Minimal Residual Disease Hematologic Malignancies After Allogeneic...

Medical condition: recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10005329 - Blood and lymphatic system disorders	10018849	Haematological disorders NEC	HLGT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: IT (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2016-000286-23

Sponsor Protocol Number: MS200662_0001

Start Date*: 2016-04-27

Sponsor Name:Telios Pharma, Inc.

Full Title: Phase I/II, First in Human, Dose Escalation Trial of TL-895 in Subjects with Relapsed/Refractory B-Cell Malignancies and Expansion in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia ...

Medical condition: B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004851	10003900	B-cell lymphomas NEC	HLT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10008976	Chronic lymphocytic leukemia	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10003908	B-cell small lymphocytic lymphoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) HU (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2010-023040-32

Sponsor Protocol Number: ROMI-ADVM-004

Start Date*: 2011-05-05

Sponsor Name:Celgene Corporation

Full Title: A phase IV, Open-Label, Single-Arm ROLLOVER STUDY FOR SUBJECTS WHO PARTICIPATED IN OTHER ROMIDEPSIN PROTOCOLS. Estudio de extensión de fase IV, abierto, de un solo brazo para pacientes que hayan p...

Medical condition: Rollover study supporting all indications from prior Romidepsin protocols eligible for participation in this study. Estudio de extensión que recoge todas las indicaciones de protocolos anteriores d...

Disease:	Version	SOC Term	Classification Code	Term	Level
	12.1		10001414	Adult T-cell lymphomas/leukaemias	HLT
	12.1		10042971	T-cell lymphoma	LLT
	12.1		10042979	T-cell lymphoma recurrent	LLT
	12.1		10042980	T-cell lymphoma refractory	LLT
	12.1		10042981	T-cell lymphoma stage I	LLT
	12.1		10042982	T-cell lymphoma stage II	LLT
	12.1		10042983	T-cell lymphoma stage III	LLT
	12.1		10042984	T-cell lymphoma stage IV	LLT
	12.1		10002450	Angioimmunoblastic T-cell lymphomas	HLT
	12.1		10022704	Intestinal T-cell lymphomas	HLT
	12.1		10034622	Peripheral T-cell lymphomas NEC	HLT
	12.1		10042988	T-cell unclassifiable lymphomas	HLT
	12.1		10001414	Adult T-cell lymphomas/leukaemias	HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Prematurely Ended) GB (Completed)

Trial results: View results

EudraCT Number: 2022-001040-23

Sponsor Protocol Number: TranspoCART19

Start Date*: 2023-03-15

Sponsor Name:Instituto de Investigación Biomédica de Salamanca (IBSAL) - IECSCYL

Full Title: Phase I/IIa multicentre phase I/IIa study of infusion of autologous peripheral blood T lymphocytes expanded and genetically modified using Sleeping Beauty family transposons to express a chimeric a...

Medical condition: Relapsed or refractory B-cell lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004851	10003900	B-cell lymphomas NEC	HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2009-010777-20

Sponsor Protocol Number: 155-CL-031

Start Date*: 2009-12-15

Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)

Full Title: A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin’s Lymphoma Who Are Ineligible For Or Have Previously Received ...

Medical condition: CD20-positive primary or transformed diffuse large B cell lymphoma (DLBCL), grade 3 follicular lymphoma (FL) and mantle cell lymphoma (MCL).

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	12.0		10029592	Non-Hodgkin's lymphomas NEC	HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed) ES (Completed) GB (Completed)

Trial results: View results

EudraCT Number: 2017-000498-35

Sponsor Protocol Number: 1537

Start Date*: 2019-03-12

Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)

Full Title: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study

Medical condition: Advanced stage Hodgkin Lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10080208	Classical Hodgkin lymphoma	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10020206	Hodgkin's disease	PT
	20.0	10005329 - Blood and lymphatic system disorders	10020243	Hodgkin's disease NEC	HLT
	20.0	10005329 - Blood and lymphatic system disorders	10025319	Lymphomas Hodgkin's disease	HLGT
	20.0	10005329 - Blood and lymphatic system disorders	10005329	Blood and lymphatic system disorders	SOC
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029104	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	SOC

Population Age: Adults

Gender: Male, Female

Trial protocol: DK (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) SK (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2009-018083-94

Sponsor Protocol Number: IEO S513/110

Start Date*: 2010-07-29

Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA

Full Title: Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients with High-Risk Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppressio...

Medical condition: High risk Hematologic Malignancies

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10024324		HLGT
	9.1		10025323		HLGT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: (No results available)

EudraCT Number: 2009-011789-26

Sponsor Protocol Number: IELSG30

Start Date*: 2010-01-25

Sponsor Name:IELSG-International Extranodal Lymphoma Study Group

Full Title: A phase II study of R-CHOP with intensive CNS prophylaxis and scrotal irradiation in patients with primary testicular diffuse large B-cell lymphoma

Medical condition: primary testicular lymphoma diffuse large B-cell

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10003900		HLT

Population Age: In utero, Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly

Gender: Male

Trial protocol: IT (Completed)

Trial results: View results

EudraCT Number: 2017-003680-35

Sponsor Protocol Number: 1652-CLTF

Start Date*: 2019-01-31

Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)

Full Title: Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IV mycosis fungoides/sezary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT)

Medical condition: Subtypes of Cutaneous T cell ltymphoma (CTCL): Mycosis Fungoides (MF) and Sézary Syndrome (SS)

Disease:	Version	SOC Term	Classification Code	Term	Level
	22.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10028508	Mycosis fungoides/Sezary syndrome	LLT
	22.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10028483	Mycosis fungoides	LLT
	20.0	10005329 - Blood and lymphatic system disorders	10028484	Mycoses fungoides	HLT
	20.0	10005329 - Blood and lymphatic system disorders	10025321	Lymphomas non-Hodgkin's T-cell	HLGT
	20.0	10005329 - Blood and lymphatic system disorders	10005329	Blood and lymphatic system disorders	SOC
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029104	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	SOC
	20.0	10040785 - Skin and subcutaneous tissue disorders	10042356	Skin and subcutaneous conditions NEC	HLT
	20.0	10040785 - Skin and subcutaneous tissue disorders	10040790	Skin and subcutaneous tissue disorders NEC	HLGT
	20.0	10040785 - Skin and subcutaneous tissue disorders	10040785	Skin and subcutaneous tissue disorders	SOC

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) AT (Completed) GR (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2014-000584-41

Sponsor Protocol Number: BP-004

Start Date*: 2014-10-23

Sponsor Name:Bellicum Pharmaceuticals, Inc.

Full Title: Phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR αβ+ T cells in pediatric patients affected by hematological disorders

Medical condition: Hematological disorders (ALL;AML;Non-Hodgkin lymphoma;Myelodysplastic syndromes;Congenital immune deficiencies;Severe aplastic anemia;Fanconi anemia; Osteopetrosis;Selected cases of hemoglobinopath...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	16.1	10005329 - Blood and lymphatic system disorders	10018849	Haematological disorders NEC	HLGT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended)

Trial results: View results

EudraCT Number: 2015-003516-21

Sponsor Protocol Number: MEDI4736-NHL-001

Start Date*: 2016-04-13

Sponsor Name:Celgene International II Sàrl

Full Title: A Phase 1/2, open label, multicenter study to assess the safety and tolerability of durvalumab (anti-PD-L1 antibody) as monotherapy and in combination therapy in subjects with lymphoma or chronic l...

Medical condition: Relapsed/refractory (R/R) lymphoma or R/R chronic lymphocytic leukemia (CLL) previously treated with at least one systemic therapy

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004851	10029592	Non-Hodgkin's lymphomas NEC	HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2018-003969-33

Sponsor Protocol Number: IPH4102-201

Start Date*: 2019-03-05

Sponsor Name:Innate Pharma SA

Full Title: TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in p...

Medical condition: Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL) and Peripheral T Cell Lympomas (PTCL). CTCL subtypes under investigation: relapsed/refractory Sézary Syndrome (SS), stage IB...

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004851	10034622	Peripheral T-cell lymphomas NEC	HLT
	20.0	100000004851	10002450	Angioimmunoblastic T-cell lymphomas	HLT
	20.0	100000004851	10002235	Anaplastic large cell lymphomas T- and-cell types	HLT
	20.0	100000004851	10028484	Mycoses fungoides	HLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) ES (Temporarily Halted) IT (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) AT (Completed)

Trial results: (No results available)

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials for Lymphomas NEC